Tehreem Fatima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tehreem Fatima has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Harsh Kumar
Department of Medicine Dow University of Health Sciences Karachi Pakistan
2 shared publications - Abdullah Nadeem
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Adrian Muntean
Karlstad University
1 shared publication - Amna Shakeel
Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Aneesh Kumar Sangtiani
Department of Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Anzel Saeed
Department of Medicine Dow University of Health Sciences Karachi Pakistan
1 shared publication
Latest Publications
- Open Access
- 29 April 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (5) , e71458
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches
Purpose of Review : This review aims to provide a comprehensive analysis of chronic inflammatory demyelinating polyneuropathy (CIDP), focusing on its clinical manifestations, pathophysiology, and treatment advancements, with particular emphasis on efgartigimod as a novel therapeutic agent. Recent Findings : CIDP is a chronic autoimmune disorder caused by demyelination and axonal degeneration, leading to progressive weakness and impaired sensory function. While conventional treatments, including corticosteroids, IVIg, and plasma exchange, provide symptomatic relief, their limitations include significant side effects and resistance in some cases. Efgartigimod, an FcRn blocker targeting the IgG catabolic pathway, has emerged as a promising therapy. The ADHERE study demonstrated a 61% reduction in CIDP relapses with efgartigimod, alongside improved disability scores and a favorable safety profile. Summary : CIDP presents significant diagnostic and therapeutic challenges, requiring tailored approaches to management. Efgartigimod introduces a targeted mechanism of action, offering hope for patients unresponsive to traditional therapies. Further research is needed to establish its long‐term efficacy and optimal role in CIDP treatment strategies.
- 29 April 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (5) , e71458
Open AccessChronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches
Purpose of Review : This review aims to provide a comprehensive analysis of chronic inflammatory demyelinating polyneuropathy (CIDP), focusing on its clinical manifestations, pathophysiology, and treatment advancements, with particular emphasis on efgartigimod as a novel therapeutic agent. Recent Findings : CIDP is a chronic autoimmune disorder caused by demyelination and axonal degeneration, leading to progressive weakness and impaired sensory function. While conventional treatments, including corticosteroids, IVIg, and plasma exchange, provide symptomatic relief, their limitations include significant side effects and resistance in some cases. Efgartigimod, an FcRn blocker targeting the IgG catabolic pathway, has emerged as a promising therapy. The ADHERE study demonstrated a 61% reduction in CIDP relapses with efgartigimod, alongside improved disability scores and a favorable safety profile. Summary : CIDP presents significant diagnostic and therapeutic challenges, requiring tailored approaches to management. Efgartigimod introduces a targeted mechanism of action, offering hope for patients unresponsive to traditional therapies. Further research is needed to establish its long‐term efficacy and optimal role in CIDP treatment strategies.
- 15 September 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (6) , 3176-3186
Selective Intracoronary Hypothermia in Percutaneous Coronary Intervention: Current Evidence, Challenges, and Future Directions
Background: Selective intracoronary hypothermia (SICH) is a promising therapeutic approach aimed at mitigating ischemia‐reperfusion injury (IRI) in patients undergoing percutaneous coronary intervention (PCI), a procedure used to address blocked or narrowed coronary arteries. This technique involves the infusion of cooled saline or cardioplegic solutions directly into the coronary arteries near the lesion, inducing localized cooling of myocardial tissue to protect against damage caused by the restoration of blood flow. Objective: Early studies indicate that SICH is a safe and feasible method that may potentially reduce infarct size and enhance myocardial recovery. Current Challenges: However, the clinical implementation of SICH is currently limited due to certain challenges including the need for specialized equipment, the risk of cooling‐related complications such as arrhythmias, and the requirement for precise temperature control. Furthermore, the ideal temperature and duration for effective cooling remain unclear. Future Directions: Addressing these challenges, future investigations should prioritize large‐scale, long‐term trials focusing on the long‐term effects of SICH on patient outcomes such as infarct size, cardiac function, and survival to confirm the efficacy and safety of this therapy. Additionally, comparative studies with other established reperfusion strategies are also required to evaluate the relative effectiveness of SICH and optimize its use during PCI.
- 15 September 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (6) , 3176-3186
Selective Intracoronary Hypothermia in Percutaneous Coronary Intervention: Current Evidence, Challenges, and Future Directions
Background: Selective intracoronary hypothermia (SICH) is a promising therapeutic approach aimed at mitigating ischemia‐reperfusion injury (IRI) in patients undergoing percutaneous coronary intervention (PCI), a procedure used to address blocked or narrowed coronary arteries. This technique involves the infusion of cooled saline or cardioplegic solutions directly into the coronary arteries near the lesion, inducing localized cooling of myocardial tissue to protect against damage caused by the restoration of blood flow. Objective: Early studies indicate that SICH is a safe and feasible method that may potentially reduce infarct size and enhance myocardial recovery. Current Challenges: However, the clinical implementation of SICH is currently limited due to certain challenges including the need for specialized equipment, the risk of cooling‐related complications such as arrhythmias, and the requirement for precise temperature control. Furthermore, the ideal temperature and duration for effective cooling remain unclear. Future Directions: Addressing these challenges, future investigations should prioritize large‐scale, long‐term trials focusing on the long‐term effects of SICH on patient outcomes such as infarct size, cardiac function, and survival to confirm the efficacy and safety of this therapy. Additionally, comparative studies with other established reperfusion strategies are also required to evaluate the relative effectiveness of SICH and optimize its use during PCI.
- 1 May 2014
- Published by Elsevier in Applied Mathematical Modelling
- Vol. 38 (9-10) , 2463-2475
Is adding charcoal to soil a good method for CO 2 sequestration? – Modeling a spatially homogeneous soil
- 1 May 2014
- Published by Elsevier in Applied Mathematical Modelling
- Vol. 38 (9-10) , 2463-2475
Is adding charcoal to soil a good method for CO 2 sequestration? – Modeling a spatially homogeneous soil
- Open Access
- 28 April 2006
- Published by Springer Nature in Astrophysics and Space Science
- Vol. 302 (1-4) , 217-224
Energy Distribution Associated with Static Axisymmetric Solutions
- 28 April 2006
- Published by Springer Nature in Astrophysics and Space Science
- Vol. 302 (1-4) , 217-224
Open AccessEnergy Distribution Associated with Static Axisymmetric Solutions
- Open Access
- 1 April 2004
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 36 (2) , 110-115
Association study of the angiotensin-converting enzyme (ACE) gene G2350A dimorphism with myocardial infarction
The angiotensin converting enzyme (ACE) is a strong candidate gene for myocardial infarction (MI). Insertion-deletion dimorphism in intron 16 of this gene has been inconclusively found to be associated with it. Several new polymorphisms in the ACE gene have been identified and among these, a dimorphism in exon 17, ACE G2350A, has a significant effect on plasma ACE concentrations. To assess the value of genotyping the ACE G2350A dimorphism in a genetically homogeneous population, we carried out a case-control study of dimorphism G2350A for a putative association with MI among Pakistani nationals. We investigated a sample population of 370 Pakistanis, comprising 163 controls, and 207 patients with clinical diagnosis of acute MI (AMI). ACE G2350A alleles were visualized by assays based on polymerase chain reaction and restriction endonuclease analysis. Frequencies of G alleles were 0.68 among controls and 0.72 among AMI patients. The ACE G2350A dimorphism showed no significant association with MI (χ2=0.90, 2 df, P=0.64), plasma levels of homocysteine (P=0.52) or with serum levels of folate (P=0.299). The results indicate that ACE G2350A polymorphism is not associated with risk of myocardial infarction in the Pakistani population investigated here.
- 1 April 2004
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 36 (2) , 110-115
Open AccessAssociation study of the angiotensin-converting enzyme (ACE) gene G2350A dimorphism with myocardial infarction
The angiotensin converting enzyme (ACE) is a strong candidate gene for myocardial infarction (MI). Insertion-deletion dimorphism in intron 16 of this gene has been inconclusively found to be associated with it. Several new polymorphisms in the ACE gene have been identified and among these, a dimorphism in exon 17, ACE G2350A, has a significant effect on plasma ACE concentrations. To assess the value of genotyping the ACE G2350A dimorphism in a genetically homogeneous population, we carried out a case-control study of dimorphism G2350A for a putative association with MI among Pakistani nationals. We investigated a sample population of 370 Pakistanis, comprising 163 controls, and 207 patients with clinical diagnosis of acute MI (AMI). ACE G2350A alleles were visualized by assays based on polymerase chain reaction and restriction endonuclease analysis. Frequencies of G alleles were 0.68 among controls and 0.72 among AMI patients. The ACE G2350A dimorphism showed no significant association with MI (χ2=0.90, 2 df, P=0.64), plasma levels of homocysteine (P=0.52) or with serum levels of folate (P=0.299). The results indicate that ACE G2350A polymorphism is not associated with risk of myocardial infarction in the Pakistani population investigated here.